SlideShare a Scribd company logo
2
Most read
4
Most read
8
Most read
Determination of Dose
and Dosing Interval
Dr. Ramesh Bhandari
Asst. Professor
Department of Pharmacy
Practice
KLE College of Pharmacy,
Belagavi
Dr.RameshBhandari
Asst.Professor  Calculation of the starting dose of a drug
and dosing interval is based on the objective
of delivering a desirable (target)
therapeutic level of the drug in the body.
 For many drugs, the desirable therapeutic
drug levels and pharmacokinetic
parameters are available in the literature.
Dr.RameshBhandari
Asst.Professor
 However, In some cases, literature may
not have complete drug information then,
pharmacokineticist must make certain
necessary assumptions in accordance with
the best pharmacokinetic information
available.
Dr.RameshBhandari
Asst.Professor
 For a drug that is given in multiple doses
for an extended period of time, the dosage
regimen is usually calculated to maintain
the average steady-state blood level within
the therapeutic range and given by
following equation:
C∞
av = 1.44D0t1/2F
Vd τ
Dr.RameshBhandari
Asst.Professor Examples:
1. Pharmacokinetic data for clindamycin were
reported by DeHaan et al (1972) as follows:
K=0.247h-1, t1/2=2.81h, Vd=43.9L/1.73M2
What is the steady-state concentration of the
drug after 150 mg of the drug is given orally
every 6 hours for a week? (Assume the drug
is 100% absorbed.)
Dr.RameshBhandari
Asst.Professor
Solution:
C∞
av = 1.44D0t1/2F
Vd τ
C∞
av = 1.44x1,50,000x2.81x1
43900x6
C∞
av = 2.3mcg/ml
Dr.RameshBhandari
Asst.Professor Example: 2
2. According to Regamey et al (1973), the
elimination half-life of tobramycin was
reported to be 2.15 hours and the volume of
distribution was reported to be 33.5% of
body weight.
What is the dose for an 80-kg individual if a
steady-state level of 2.5 μg/mL is desired?
Assume that the drug is given by intravenous
bolus injection every 8 hours
Dr.RameshBhandari
Asst.Professor
Determination of Both Dose and
Dosage Interval
Both the dose and the dosing
interval should be considered in the
dosage regimen calculations.
For Intravenous multiple-dosage
regimens, the ratio of C∞
max / C∞
min
may be expressed by:
Dr.RameshBhandari
Asst.Professor C∞
max = C0
p/(1 - e-k τ)
C ∞
min C0
p e-k τ (1 - e-k τ)
C∞
max = 1
C∞
min e-k τ
From above equation, a maximum dosage interval (τ), may be
calculated that will maintain the serum concentration between desired
C ∞
min and C ∞
max. After the dosage interval is calculated, then a dose
may be calculated.
Dr.RameshBhandari
Asst.Professor
Example:1
 The elimination half-life of an antibiotic is 3
hours with an apparent volume of distribution
equivalent to 20% of body weight. The usual
therapeutic range for this antibiotic is between
5 and 15 μg/mL. Adverse toxicity for this drug
is often observed at serum concentrations
greater than 20 μg/mL. Calculate a dosage
regimen (multiple IV doses) that will just
maintain the serum drug concentration
between 5 and 15 μg/mL.
Dr.RameshBhandari
Asst.Professor
Solution:
Determine the maximum possible
dosage interval (τ).
Determine the dose required to produce
from C∞
max
C∞
max = D0 / Vd
1 – e-Kτ
Dr.RameshBhandari
Asst.Professor
Effect of changing dose and
dosing interval on C∞
min, C∞
max
and C∞
av.
 During intravenous infusion, Css may be
used to monitor the steady-state serum
concentrations.
 When considering TDM of serum
concentrations after the initiation of a
multiple-dosage regimen, the trough serum
drug concentrations or C∞
min may be used
to validate the dosage regimen.
Dr.RameshBhandari
Asst.Professor
 The blood sample withdrawn just prior to
the administration of the next dose
represents C∞
min.
 To obtain C∞
max , the blood sample must be
withdrawn exactly at the time for peak
absorption.
Dr.RameshBhandari
Asst.Professor  In practice, an approximate time for
maximum drug absorption is estimated
and a blood sample is withdrawn.
 Because of difference in absorption rate,
C∞
max obtained is only approximation
rather than true value.
 So the C∞
av is used most oftenly for
dosage calculation.
Dr.RameshBhandari
Asst.Professor  The advantage of using C∞
av as an
indicator for deciding therapeutic blood
level is that C∞
av is determined on a set of
points and generally fluctuates less than
either C∞
max or C∞
min.
 Moreover, when the dosing interval is
changed, the dose may be increased
proportionally, to keep C∞
av constant.
Dr.RameshBhandari
Asst.Professor
 In general, if a drug has a relatively wide
therapeutic index and a relatively long
elimination half-life, then flexibility exists
in changing the dose or dosing interval
(τ), using C∞
av as an indicator.
 When the drug has a narrow therapeutic
index, C∞
max and C∞
min must be monitored
to ensure safety and efficacy.
Dr.RameshBhandari
Asst.Professor  As the dose or dosage intervals change
proportionately, the C∞
av may be the same but
the steady state peak, C∞
max , and trough, C∞
min ,
drug levels will change.
 C∞
max is influenced by the dose and the dosage
interval.
 An increase in the dose given at a longer
dosage interval will cause an increase in C∞
max
and a decrease in C∞
min.
Dr.RameshBhandari
Asst.Professor

More Related Content

PPTX
NOMOGRAMS AND TABULATIONS IN DESIGNING DOSAGE REGIMEN.pptx
PPTX
Individualization of drug dosage regimen
DOCX
conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimen
PDF
TDM of drugs used in seizure disorders
PDF
Population pharmacokinetics
PDF
Bayesian theory
PPTX
Dosing in elderly
PPTX
Therapeutic drug monitoring of organ transplantation drugs
NOMOGRAMS AND TABULATIONS IN DESIGNING DOSAGE REGIMEN.pptx
Individualization of drug dosage regimen
conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimen
TDM of drugs used in seizure disorders
Population pharmacokinetics
Bayesian theory
Dosing in elderly
Therapeutic drug monitoring of organ transplantation drugs

What's hot (20)

PDF
Designing of dosage regimen
PDF
SOFTWARE USED IN P'epidemiology.pdf
PPTX
Drug dosing in elderly, infant and obese patient slide share
PPTX
Protocol for tdm
PPTX
Pharmacokinetic and pharmacodynamic correlation
PPTX
Studies of vaccine safety (Pharmacoepidemiology) V PharmD
DOCX
Adaptive method OR dosing with feedback
PPTX
DRUG USE MEASURES.pptx
PPTX
Design of Dosage form
DOCX
Introduction to Bayesian theory
PPTX
6. population pharmacokinetics
PDF
Nomograms and tabulations in design of dosage regimens
PDF
TDM of psychiatric drugs
PPTX
Abbreviated new drug application submission
PPTX
Individualization of dosage regimen
PDF
Introduction to clinical pharmacokinetics
PPT
Individualization of dosage regime
PPTX
DESIGN OF DOSAGE REGIMEN.pptx
PPTX
Population pharamacokinetics
PPTX
Pharmacoeconomics pptx
Designing of dosage regimen
SOFTWARE USED IN P'epidemiology.pdf
Drug dosing in elderly, infant and obese patient slide share
Protocol for tdm
Pharmacokinetic and pharmacodynamic correlation
Studies of vaccine safety (Pharmacoepidemiology) V PharmD
Adaptive method OR dosing with feedback
DRUG USE MEASURES.pptx
Design of Dosage form
Introduction to Bayesian theory
6. population pharmacokinetics
Nomograms and tabulations in design of dosage regimens
TDM of psychiatric drugs
Abbreviated new drug application submission
Individualization of dosage regimen
Introduction to clinical pharmacokinetics
Individualization of dosage regime
DESIGN OF DOSAGE REGIMEN.pptx
Population pharamacokinetics
Pharmacoeconomics pptx
Ad

Similar to Determination of dose and dosing interval (20)

PDF
Determination of dose and dosing interval
PPTX
Determination of dose & dosing interval- V Pharm.D.pptx
PPTX
2. Basic Phk-IV and EV.pptx
PDF
multiple-dosage-regimen.pdf
PPTX
Multiple Dosage regimen
PDF
Pharmacokinetics / Biopharmaceutics - Multi dosage regimens
PPTX
Kinetics of multiple dosing
PPTX
Dosage regimen designing, determination of dose and dosing interval
PDF
Biopharmaceutics: Multiple dosage regimens
PPT
05_Multiple dosing IV bolus.ppt
PPTX
2- MULTIPLE-ORAL-DOSE REGIMEN.pptx pharmacy
PDF
MULTIPLE DOSAGE REGIMEN-REPETITIVE PROFILES.pdf
PDF
Application of pharmacokinetics
PPTX
Pharmacokinetics of multiple dosing
PDF
Pharmacokinetics & BA - Part-2.pdf
PDF
Pharmacokinetics & BA - Part-2.pdf
PPTX
Introduction to dosage regimen and Individualization of dosage regimen
PPTX
Multiple Dosage Oral Administration/ Dosage Regimen
PPTX
Therapeutic drug monitoring LECTURE 2.pptx pharmaceutical sciences
Determination of dose and dosing interval
Determination of dose & dosing interval- V Pharm.D.pptx
2. Basic Phk-IV and EV.pptx
multiple-dosage-regimen.pdf
Multiple Dosage regimen
Pharmacokinetics / Biopharmaceutics - Multi dosage regimens
Kinetics of multiple dosing
Dosage regimen designing, determination of dose and dosing interval
Biopharmaceutics: Multiple dosage regimens
05_Multiple dosing IV bolus.ppt
2- MULTIPLE-ORAL-DOSE REGIMEN.pptx pharmacy
MULTIPLE DOSAGE REGIMEN-REPETITIVE PROFILES.pdf
Application of pharmacokinetics
Pharmacokinetics of multiple dosing
Pharmacokinetics & BA - Part-2.pdf
Pharmacokinetics & BA - Part-2.pdf
Introduction to dosage regimen and Individualization of dosage regimen
Multiple Dosage Oral Administration/ Dosage Regimen
Therapeutic drug monitoring LECTURE 2.pptx pharmaceutical sciences
Ad

More from Dr. Ramesh Bhandari (20)

PDF
Designing Protocol.pdf
PDF
Communicable diseases
PDF
Causality Assessment ADR.pdf
PDF
Microbiological culture sensitivity tests
PDF
Respiratory and Intestinal infections
PDF
Epidemiology
PDF
Microbiology
PDF
Nutrition and Food
PDF
Effect of environment on health
PDF
Vaccine and immunity
PDF
Psychosocial pharmacy
PDF
PDF
Mother and child health
PDF
Demography, demographic cycle and family planning methods
PDF
National health policy, MDGs, SDPs, and FIP Development Goals
PDF
Concept, Dimension, Determinants, and Indicators of health
PDF
Social pharmacy, National Health Mission
PDF
Safety Data Generation
PDF
ICH Guidelines for Pharmacovigilance
PDF
Pharmacovigilance methods
Designing Protocol.pdf
Communicable diseases
Causality Assessment ADR.pdf
Microbiological culture sensitivity tests
Respiratory and Intestinal infections
Epidemiology
Microbiology
Nutrition and Food
Effect of environment on health
Vaccine and immunity
Psychosocial pharmacy
Mother and child health
Demography, demographic cycle and family planning methods
National health policy, MDGs, SDPs, and FIP Development Goals
Concept, Dimension, Determinants, and Indicators of health
Social pharmacy, National Health Mission
Safety Data Generation
ICH Guidelines for Pharmacovigilance
Pharmacovigilance methods

Recently uploaded (20)

PPT
Copy-Histopathology Practical by CMDA ESUTH CHAPTER(0) - Copy.ppt
PPT
OPIOID ANALGESICS AND THEIR IMPLICATIONS
PPTX
NEET PG 2025 Pharmacology Recall | Real Exam Questions from 3rd August with D...
PDF
CT Anatomy for Radiotherapy.pdf eryuioooop
PPTX
surgery guide for USMLE step 2-part 1.pptx
PPTX
Uterus anatomy embryology, and clinical aspects
PPT
MENTAL HEALTH - NOTES.ppt for nursing students
PPTX
post stroke aphasia rehabilitation physician
PPTX
JUVENILE NASOPHARYNGEAL ANGIOFIBROMA.pptx
PPTX
DENTAL CARIES FOR DENTISTRY STUDENT.pptx
PPTX
POLYCYSTIC OVARIAN SYNDROME.pptx by Dr( med) Charles Amoateng
PPTX
neonatal infection(7392992y282939y5.pptx
PPT
Obstructive sleep apnea in orthodontics treatment
PPT
Management of Acute Kidney Injury at LAUTECH
PPTX
CEREBROVASCULAR DISORDER.POWERPOINT PRESENTATIONx
PPTX
Electromyography (EMG) in Physiotherapy: Principles, Procedure & Clinical App...
PPTX
Fundamentals of human energy transfer .pptx
PPT
ASRH Presentation for students and teachers 2770633.ppt
PPTX
History and examination of abdomen, & pelvis .pptx
PDF
Therapeutic Potential of Citrus Flavonoids in Metabolic Inflammation and Ins...
Copy-Histopathology Practical by CMDA ESUTH CHAPTER(0) - Copy.ppt
OPIOID ANALGESICS AND THEIR IMPLICATIONS
NEET PG 2025 Pharmacology Recall | Real Exam Questions from 3rd August with D...
CT Anatomy for Radiotherapy.pdf eryuioooop
surgery guide for USMLE step 2-part 1.pptx
Uterus anatomy embryology, and clinical aspects
MENTAL HEALTH - NOTES.ppt for nursing students
post stroke aphasia rehabilitation physician
JUVENILE NASOPHARYNGEAL ANGIOFIBROMA.pptx
DENTAL CARIES FOR DENTISTRY STUDENT.pptx
POLYCYSTIC OVARIAN SYNDROME.pptx by Dr( med) Charles Amoateng
neonatal infection(7392992y282939y5.pptx
Obstructive sleep apnea in orthodontics treatment
Management of Acute Kidney Injury at LAUTECH
CEREBROVASCULAR DISORDER.POWERPOINT PRESENTATIONx
Electromyography (EMG) in Physiotherapy: Principles, Procedure & Clinical App...
Fundamentals of human energy transfer .pptx
ASRH Presentation for students and teachers 2770633.ppt
History and examination of abdomen, & pelvis .pptx
Therapeutic Potential of Citrus Flavonoids in Metabolic Inflammation and Ins...

Determination of dose and dosing interval

  • 1. Determination of Dose and Dosing Interval Dr. Ramesh Bhandari Asst. Professor Department of Pharmacy Practice KLE College of Pharmacy, Belagavi
  • 2. Dr.RameshBhandari Asst.Professor  Calculation of the starting dose of a drug and dosing interval is based on the objective of delivering a desirable (target) therapeutic level of the drug in the body.  For many drugs, the desirable therapeutic drug levels and pharmacokinetic parameters are available in the literature.
  • 3. Dr.RameshBhandari Asst.Professor  However, In some cases, literature may not have complete drug information then, pharmacokineticist must make certain necessary assumptions in accordance with the best pharmacokinetic information available.
  • 4. Dr.RameshBhandari Asst.Professor  For a drug that is given in multiple doses for an extended period of time, the dosage regimen is usually calculated to maintain the average steady-state blood level within the therapeutic range and given by following equation: C∞ av = 1.44D0t1/2F Vd τ
  • 5. Dr.RameshBhandari Asst.Professor Examples: 1. Pharmacokinetic data for clindamycin were reported by DeHaan et al (1972) as follows: K=0.247h-1, t1/2=2.81h, Vd=43.9L/1.73M2 What is the steady-state concentration of the drug after 150 mg of the drug is given orally every 6 hours for a week? (Assume the drug is 100% absorbed.)
  • 6. Dr.RameshBhandari Asst.Professor Solution: C∞ av = 1.44D0t1/2F Vd τ C∞ av = 1.44x1,50,000x2.81x1 43900x6 C∞ av = 2.3mcg/ml
  • 7. Dr.RameshBhandari Asst.Professor Example: 2 2. According to Regamey et al (1973), the elimination half-life of tobramycin was reported to be 2.15 hours and the volume of distribution was reported to be 33.5% of body weight. What is the dose for an 80-kg individual if a steady-state level of 2.5 μg/mL is desired? Assume that the drug is given by intravenous bolus injection every 8 hours
  • 8. Dr.RameshBhandari Asst.Professor Determination of Both Dose and Dosage Interval Both the dose and the dosing interval should be considered in the dosage regimen calculations. For Intravenous multiple-dosage regimens, the ratio of C∞ max / C∞ min may be expressed by:
  • 9. Dr.RameshBhandari Asst.Professor C∞ max = C0 p/(1 - e-k τ) C ∞ min C0 p e-k τ (1 - e-k τ) C∞ max = 1 C∞ min e-k τ From above equation, a maximum dosage interval (τ), may be calculated that will maintain the serum concentration between desired C ∞ min and C ∞ max. After the dosage interval is calculated, then a dose may be calculated.
  • 10. Dr.RameshBhandari Asst.Professor Example:1  The elimination half-life of an antibiotic is 3 hours with an apparent volume of distribution equivalent to 20% of body weight. The usual therapeutic range for this antibiotic is between 5 and 15 μg/mL. Adverse toxicity for this drug is often observed at serum concentrations greater than 20 μg/mL. Calculate a dosage regimen (multiple IV doses) that will just maintain the serum drug concentration between 5 and 15 μg/mL.
  • 11. Dr.RameshBhandari Asst.Professor Solution: Determine the maximum possible dosage interval (τ). Determine the dose required to produce from C∞ max C∞ max = D0 / Vd 1 – e-Kτ
  • 12. Dr.RameshBhandari Asst.Professor Effect of changing dose and dosing interval on C∞ min, C∞ max and C∞ av.  During intravenous infusion, Css may be used to monitor the steady-state serum concentrations.  When considering TDM of serum concentrations after the initiation of a multiple-dosage regimen, the trough serum drug concentrations or C∞ min may be used to validate the dosage regimen.
  • 13. Dr.RameshBhandari Asst.Professor  The blood sample withdrawn just prior to the administration of the next dose represents C∞ min.  To obtain C∞ max , the blood sample must be withdrawn exactly at the time for peak absorption.
  • 14. Dr.RameshBhandari Asst.Professor  In practice, an approximate time for maximum drug absorption is estimated and a blood sample is withdrawn.  Because of difference in absorption rate, C∞ max obtained is only approximation rather than true value.  So the C∞ av is used most oftenly for dosage calculation.
  • 15. Dr.RameshBhandari Asst.Professor  The advantage of using C∞ av as an indicator for deciding therapeutic blood level is that C∞ av is determined on a set of points and generally fluctuates less than either C∞ max or C∞ min.  Moreover, when the dosing interval is changed, the dose may be increased proportionally, to keep C∞ av constant.
  • 16. Dr.RameshBhandari Asst.Professor  In general, if a drug has a relatively wide therapeutic index and a relatively long elimination half-life, then flexibility exists in changing the dose or dosing interval (τ), using C∞ av as an indicator.  When the drug has a narrow therapeutic index, C∞ max and C∞ min must be monitored to ensure safety and efficacy.
  • 17. Dr.RameshBhandari Asst.Professor  As the dose or dosage intervals change proportionately, the C∞ av may be the same but the steady state peak, C∞ max , and trough, C∞ min , drug levels will change.  C∞ max is influenced by the dose and the dosage interval.  An increase in the dose given at a longer dosage interval will cause an increase in C∞ max and a decrease in C∞ min.